Yazar "Aydin, Dincer" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Comprehensive analysis of impacts of lymph node yield on patient survival and recurrence in patients with stage II rectal cancer: A single institution study
    (2019) Civil, Osman; Okkabaz, Nuri; Sahin, Tevfik Tolga; Yazicioglu, Murat Burc; Tiryaki, Çağrı; Gunes, Abdullah; Ciftci, Ali; Aydin, Dincer
    Aim: Pathologic evaluation of rectal cancer is very important. Lymph node yields may be related to surgical technique or inadequate harvesting in the pathology department. The importance of lymph node yields >12 have been emphasized by many researchers to be adequate for staging. In stage II rectal cancer, the impacts of lymph node yield on locoregional recurrence and patient survival have not been studied. The aim of the present study is to evaluate the impact of lymph node yield on outcome and prognosis of the patients with stage II rectal cancer. Material and Methods: Patients with stage II rectal cancer who were operated in our institution between 2008 and 2013 were retrospectively analyzed to determine the impact of lymph node yield on survival, locoregional and distant metastasis.Results: Overall, local and distant recurrence rates were 13.9%, 4.65% and 9.30%; respectively. We did not find any significant difference in terms of locoregional and distant metastasis rates among Group I (lymph node12) (p>0.05). The 5-year survival of the patients in Group 1 versus Group 2 were 86.7% versus 82%; respectively (p>0.05). Conclusions: Results of the present study emphasize that lymph node yields may not have an impact on patient survival or recurrence. However, the patient groups were heterogeneous and the volume was low, therefore, more studies with higher volumes are needed. Keywords: Rectal Cancer; Staging; Lymph Node Metastasis.
  • Küçük Resim Yok
    Öğe
    Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)
    (Imprimatur Publications, 2016) Aydin, Dincer; Sendur, Mehmet Ali; Kefeli, Umut; Unal, Olcun Umut; Tastekin, Didem; Akyol, Murat; Tanrikulu, Eda
    Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods: Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive care (BSC). Results: Of the 71 patients, 42 (59%) were male and 29 (41%) female with a median age of 56 years. Median follow-up duration was 14.3 months. The median progression free survival (PFS) and overall survival (OS) were 7 and 13 months, respectively (N=71). In patients treated with FOLFOX (N=18), FOLFIRI (N=11), cisplatin-5-fluoroura-cil/5-FU (N=17) and gemcitabine alone (N=10), median PFS was 7, 8, 8 and 5 months, respectively, while median OS was 15, 16, 15 and 11 months, respectively. No significant differences between chemotherapy groups were noticed in terms of PFS and OS. Univariate analysis revealed that chemotherapy administration, de novo metastatic disease, ECOG PS 0 and 1, and overall response to therapy were significantly related to improved outcome. Only overall response to treatment was found to be significantly prognostic in multivariate analysis (p = 0.001). Conclusions: In this study, overall response to chemotherapy emerged as the single significant prognostic factor for advanced SBAs. Platin and irinotecan based regimens achieved similar survival outcomes in advanced SBA patients.